The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Sep 23

PMID 36140259

Authors

Zaria Malindi

Stefan Barth

Heidi Abrahamse

Affiliations

Soon will be listed here.

Abstract

Melanoma is highly aggressive and is known to be efficient at resisting drug-induced apoptotic signals. Resection is currently the gold standard for melanoma management, but it only offers local control of the early stage of the disease. Metastatic melanoma is prone to recurrence, and has a poor prognosis and treatment response. Thus, the need for advanced theranostic alternatives is evident. Photodynamic therapy has been increasingly studied for melanoma treatment; however, it relies on passive drug accumulation, leading to off-target effects. Nanoparticles enhance drug biodistribution, uptake and intra-tumoural concentration and can be functionalised with monoclonal antibodies that offer selective biorecognition. Antibody-drug conjugates reduce passive drug accumulation and off-target effects. Nonetheless, one limitation of monoclonal antibodies and antibody-drug conjugates is their lack of versatility, given cancer's heterogeneity. Monoclonal antibodies suffer several additional limitations that make recombinant antibody fragments more desirable. SNAP-tag is a modified version of the human DNA-repair enzyme, O6-alkylguanine-DNA alkyltransferase. It reacts in an autocatalytic and covalent manner with benzylguanine-modified substrates, providing a simple protein labelling system. SNAP-tag can be genetically fused with antibody fragments, creating fusion proteins that can be easily labelled with benzylguanine-modified payloads for site-directed delivery. This review aims to highlight the benefits and limitations of the abovementioned approaches and to outline how their combination could enhance photodynamic therapy for melanoma.

Citing Articles

Unlocking the Potential of Silver Nanoparticles: From Synthesis to Versatile Bio-Applications.

Almatroudi A Pharmaceutics. 2024; 16(9).

PMID: 39339268 PMC: 11435049. DOI: 10.3390/pharmaceutics16091232.

Cancer biotherapy: review and prospect.

Liu Q, Ma H Clin Exp Med. 2024; 24(1):114.

PMID: 38801637 PMC: 11130057. DOI: 10.1007/s10238-024-01376-2.

The fusion of light and immunity: Advancements in photoimmunotherapy for melanoma.

Volety P, Shirley C, Chhabra G, Ahmad N Photochem Photobiol. 2024; 100(4):910-922.

PMID: 38623955 PMC: 11286352. DOI: 10.1111/php.13951.

Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors.

Roa P, Bremer N, Foglizzo V, Cocco E Cancers (Basel). 2024; 16(6).

PMID: 38539548 PMC: 10968748. DOI: 10.3390/cancers16061215.

Photosensitizers-Loaded Nanocarriers for Enhancement of Photodynamic Therapy in Melanoma Treatment.

Udrea A, Smarandache A, Dinache A, Mares C, Nistorescu S, Avram S Pharmaceutics. 2023; 15(8).

PMID: 37631339 PMC: 10460031. DOI: 10.3390/pharmaceutics15082124.

References

Yang J, Price M, Li G, Bar-Eli M, Salgia R, Jagedeeswaran R . Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 2009; 69(19):7538-47. PMC: 2762355. DOI: 10.1158/0008-5472.CAN-08-4626. View

Ash C, Dubec M, Donne K, Bashford T . Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods. Lasers Med Sci. 2017; 32(8):1909-1918. PMC: 5653719. DOI: 10.1007/s10103-017-2317-4. View

Harding F, Stickler M, Razo J, DuBridge R . The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256-65. PMC: 2881252. DOI: 10.4161/mabs.2.3.11641. View

Tawbi H, Schadendorf D, Lipson E, Ascierto P, Matamala L, Castillo Gutierrez E . Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1):24-34. PMC: 9844513. DOI: 10.1056/NEJMoa2109970. View

Ning S, Lee S, Wei M, Peng C, Lin S, Tsai M . Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles. ACS Appl Mater Interfaces. 2016; 8(28):17793-804. DOI: 10.1021/acsami.6b04403. View

Zangemeister-Wittke U . Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives. Pathobiology. 2006; 72(6):279-86. DOI: 10.1159/000091325. View

Gilaberte Y, Milla L, Salazar N, Vera-Alvarez J, Kourani O, Damian A . Cellular intrinsic factors involved in the resistance of squamous cell carcinoma to photodynamic therapy. J Invest Dermatol. 2014; 134(9):2428-2437. DOI: 10.1038/jid.2014.178. View

Lan C . Effects and interactions of increased environmental temperature and UV radiation on photoageing and photocarcinogenesis of the skin. Exp Dermatol. 2019; 28 Suppl 1:23-27. DOI: 10.1111/exd.13818. View

Basu R, Qian Y, Mathes S, Terry J, Arnett N, Riddell T . Growth hormone receptor antagonism downregulates ATP-binding cassette transporters contributing to improved drug efficacy against melanoma and hepatocarcinoma . Front Oncol. 2022; 12:936145. PMC: 9296106. DOI: 10.3389/fonc.2022.936145. View

10.

Dhilip Kumar S, Rajendran N, Houreld N, Abrahamse H . Recent advances on silver nanoparticle and biopolymer-based biomaterials for wound healing applications. Int J Biol Macromol. 2018; 115:165-175. DOI: 10.1016/j.ijbiomac.2018.04.003. View

11.

Naidoo C, Kruger C, Abrahamse H . Simultaneous Photodiagnosis and Photodynamic Treatment of Metastatic Melanoma. Molecules. 2019; 24(17). PMC: 6749501. DOI: 10.3390/molecules24173153. View

12.

Turubanova V, Balalaeva I, Mishchenko T, Catanzaro E, Alzeibak R, Peskova N . Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine. J Immunother Cancer. 2019; 7(1):350. PMC: 6916435. DOI: 10.1186/s40425-019-0826-3. View

13.

Clemente N, Miletto I, Gianotti E, Invernizzi M, Marchese L, Dianzani U . Verteporfin-loaded mesoporous silica nanoparticles inhibit mouse melanoma proliferation in vitro and in vivo. J Photochem Photobiol B. 2019; 197:111533. DOI: 10.1016/j.jphotobiol.2019.111533. View

14.

Ott P, Pavlick A, Johnson D, Hart L, Infante J, Luke J . A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019; 125(7):1113-1123. DOI: 10.1002/cncr.31892. View

15.

Khristunova Y, Korotkova E, Kratochvil B, Barek J, Dorozhko E, Vyskocil V . Preparation and Investigation of Silver Nanoparticle⁻Antibody Bioconjugates for Electrochemical Immunoassay of Tick-Borne Encephalitis. Sensors (Basel). 2019; 19(9). PMC: 6540590. DOI: 10.3390/s19092103. View

16.

Pohlit H, Bellinghausen I, Schomer M, Heydenreich B, Saloga J, Frey H . Biodegradable pH-Sensitive Poly(ethylene glycol) Nanocarriers for Allergen Encapsulation and Controlled Release. Biomacromolecules. 2015; 16(10):3103-11. DOI: 10.1021/acs.biomac.5b00458. View

17.

Sullivan R, Flaherty K . MAP kinase signaling and inhibition in melanoma. Oncogene. 2012; 32(19):2373-9. DOI: 10.1038/onc.2012.345. View

18.

Obrador E, Liu-Smith F, Dellinger R, Salvador R, Meyskens F, Estrela J . Oxidative stress and antioxidants in the pathophysiology of malignant melanoma. Biol Chem. 2018; 400(5):589-612. DOI: 10.1515/hsz-2018-0327. View

19.

Di Corato R, Palumberi D, Marotta R, Scotto M, Carregal-Romero S, Rivera Gil P . Magnetic nanobeads decorated with silver nanoparticles as cytotoxic agents and photothermal probes. Small. 2012; 8(17):2731-42. DOI: 10.1002/smll.201200230. View

20.

Bertolotto C . Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo). 2014; 2013:635203. PMC: 3874946. DOI: 10.1155/2013/635203. View